A cross-sectional study evaluating treatment rates of amblyopia and strabismus in children across the United States found that greater densities of pediatric ophthalmologists were positively correlated with rates of children treated for these conditions. Source: AAO
A second patient in Michigan has been identified with the highly pathogenic avian influenza virus A(H5N1) bringing the total number of known U.S. cases to three. Source: AAO
A prospective interventional study evaluated a prototype of a device designed to be implanted in the sulcus to help treat the symptoms of negative dysphotopsia. Source: AAO
Pooled study data, involving more than 558,000 older participants, indicate that those who underwent cataract surgery appeared to have a lower risk of developing cognitive decline than those with unoperated cataracts and a similar risk to those without cataracts. Source: AAO
While there have been reports of abducens nerve palsy after COVID-19 vaccination, it is not clear if there is a direct link between the 2 events. Source: AAO
No significant adverse effects were seen in a small cohort of patients after receipt of a CRISPR-derived agent designed to target CEP290-associated inherited retinal degeneration. Source: AAO
Easy IOL fabrication via 3D printing could be possible, sociodemographic factors could influence poor vision development in children with uveitis due to juvenile idiopathic arthritis, and the jury is still out on using omega-3 fatty acid supplements for dry eye disease. Source: AAO
Investigators evaluated the reliability of Humphrey visual field testing and longitudinal change over time in children with glaucoma or glaucoma suspect, a population in which standard automated perimetry tests are not widely given. Source: AAO
The International von Hippel–Lindau (VHL) Surveillance Guidelines Consortium introduces new evidence-based recommendations for the screening and treatment of patients with VHL disease. Source: AAO
Data from the long-term Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study, conducted among ocular inflammatory disease (OID) subspecialty centers in the United States, indicate that immunosuppressive therapy for OID does not appear to increase mortality risk. Source: AAO